GSK plc (GSK) just picked up another regulatory win for its newest asthma drug. The European Commission approved Exdensur (depemokimab) on Tuesday for two separate patient populations who've been stuck with limited options despite aggressive treatment.

The first approval covers severe asthma patients dealing with type 2 inflammation, specifically those with elevated blood eosinophil counts who haven't gotten adequate relief from high-dose inhaled corticosteroids combined with another controller medication. This applies to adults and adolescents 12 years and older.

The second indication targets adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP), where neither systemic corticosteroids nor surgery have delivered sufficient disease control. For these patients, Exdensur works as an add-on therapy alongside intranasal corticosteroids.

What Makes This Drug Different

The real selling point here is convenience. Exdensur is designed as a twice-yearly treatment, which is a dramatic departure from the regular injection schedules most biologics require. The drug achieves this through high binding affinity to interleukin-5 (IL-5), high potency, and an extended half-life that keeps type 2 inflammation suppressed for months at a time.

The European approval draws on data from the SWIFT and ANCHOR phase 3 trials, which tested depemokimab as an add-on to standard care versus standard care alone. All four trials hit their primary or co-primary endpoints with results that were both statistically significant and clinically meaningful.

The Clinical Evidence

In the SWIFT-1 and SWIFT-2 trials, patients treated with depemokimab saw their annual asthma exacerbation rates drop by 58% and 48% respectively over 52 weeks. Those are substantial reductions in asthma attacks.

Perhaps more importantly, the drug appears to prevent the most dangerous outcomes. In SWIFT-1 and SWIFT-2, only 1% and 4% of depemokimab patients experienced exacerbations requiring hospitalization or emergency department visits, compared with 8% and 10% in the placebo groups. A pooled analysis of both trials showed a 72% reduction in the annual rate of these severe exacerbations over 52 weeks.

For nasal polyp patients in the ANCHOR trials, depemokimab delivered meaningful improvements in nasal polyp scores (measured on a 0-8 scale) at 52 weeks and reduced nasal obstruction over weeks 49-52.

Why This Matters

The patient populations here have been dealing with genuinely difficult conditions. More than 42 million Europeans have asthma, and roughly 5-10% experience the severe form. Many of these patients continue suffering exacerbations and diminished quality of life even with treatment. Similarly, nearly half of CRSwNP patients remain uncontrolled despite available therapies.

Exdensur's global rollout is moving quickly. The FDA approved the drug in December 2024 for severe eosinophilic asthma in patients 12 and older. The U.K. and Japan have also recently cleared the treatment for severe asthma and CRSwNP.

Price Action: GSK stock traded up 2.65% at $60.49 during Tuesday's premarket session.